SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 27, 2017

 

 

APPLIED GENETIC TECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-36370   59-3553710
(State or other jurisdiction

of incorporation)

  (Commission

File Number)

  (IRS Employer

Identification Number)

14193 NW 119 th Terrace

Suite 10

Alachua, Florida, 32165

(Address of principal executive offices) (Zip Code)

(386) 462-2204

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 27, 2017, Applied Genetic Technologies Corporation (the “Company”) entered into an employment letter agreement with William A. Sullivan (the “Employment Agreement”), pursuant to which Mr. Sullivan, 46, agreed to serve as the Company’s Chief Financial Officer beginning on August 7, 2017 in connection with the retirement of Lawrence E. Bullock, the Company’s current Chief Financial Officer. Mr. Sullivan’s employment with the Company will be on an at-will basis and the terms of the Employment Agreement provide that Mr. Sullivan will be paid an annual base salary of $340,000 and he will be eligible for annual bonus of up to 35% of his base salary as of the end of each fiscal year. Upon the occurrence of a Change of Control (as defined in the Employment Agreement) in which Mr. Sullivan is not offered the position of Chief Financial Officer of the acquirer, Mr. Sullivan’s options shall immediately be deemed fully vested and exercisable. Mr. Sullivan will also be required to enter into the Company’s standard Nondisclosure, Inventions and Non-Competition Agreement.

Provided that he has been employed for at least six months, Mr. Sullivan will be eligible to receive certain severance benefits in connection with a termination of his employment by the Company without Cause (as defined in the Employment Agreement) or by Mr. Sullivan for Good Reason (as defined in the Employment Agreement), in each case, subject to execution of a mutually acceptable release and settlement agreement. If such termination occurs during the first year of Mr. Sullivan’s employment, he shall be entitled to receive nine months of his then current base salary and if such termination occurs after the first year of his employment, he will be entitled to twelve months of his then current base salary, in each case, including the amount of any earned bonus. The Company will also continue to pay the Company portion of COBRA premiums for the nine- or twelve -month period, as applicable.

Mr. Sullivan previously served as Head of Finance, Principal Accounting Officer and Treasurer of Merrimack Pharmaceuticals, Inc. from August 2015 until April 2017. Mr. Sullivan served as Merrimack’s Chief Financial Officer and Treasurer from May 2011 to August 2015, as Vice President of Finance and Treasurer from February 2010 to May 2011 and as Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007. Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an M.B.A. and an M.S. in accounting from Northeastern University’s Graduate School of Professional Accounting and a B.A. from Williams College.

The foregoing summary of the Employment Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

On August 2, 2017, the Company also announced that it appointed Andrew Ashe as General Counsel effective as of August 1, 2017. Mr. Ashe previously served as the Executive Vice President and General Counsel of Dyax Corp. from February 2013 until January 2016. He joined Dyax in 2003 and served as an attorney in their legal department until January 2011 when he became their General Counsel. Prior to joining Dyax, Mr. Ashe practiced law as a corporate attorney at Nutter, McClennen & Fish and Prince, Lobel & Tye, two private law firms based in Boston, Massachusetts. Previously, Mr. Ashe also worked as a Trading Specialist and Senior Analyst of Corporate Listings for the New York and American Stock Exchanges. Mr. Ashe received his law degree from The George Washington School of Law and a BBA from the University of Massachusetts, Amherst.


On July 27, 2017, the Company entered into a separation agreement (the “Separation Agreement”) with Lawrence E. Bullock, our Chief Financial Officer. Pursuant to the terms of the Separation Agreement, Mr. Bullock will retire as Chief Financial Officer and be replaced by Mr. Sullivan on August 7, 2017. Notwithstanding his retirement as Chief Financial Officer, Mr. Bullock’s employment with the Company will terminate effective as of September 14, 2017 (or a date mutually agreed to by the Company and Mr. Bullock) and until such termination, he will assist with the transitioning of his current duties and responsibilities to Mr. Sullivan. During this period, he will continue to receive his current salary and benefits and, for the one-year period following the termination of his employment, the Company will contribute to the cost of COBRA continuation coverage at the same rate it contributed to Mr. Bullock’s coverage prior to such termination. In addition, subject to the achievement of certain performance goals, Mr. Bullock will be eligible to receive a bonus of up to $119,350. The Company also agreed to: (i) grant Mr. Bullock an option to purchase 4,168 shares of Common Stock, vesting in four equal monthly installments with the first installment vesting on July 31, 2017 and each successive installment vesting on the last day of each month thereafter (subject to continued employment) and (ii) to amend the options held by Mr. Bullock such that they will remain exercisable for twenty-four months following the termination of his employment. The Separation Agreement includes a release of claims against the Company and requires continued compliance with the previously-executed Nondisclosure, Inventions and Non-Competition Agreement.

The foregoing summary of the Separation Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

Exhibit No.

  

Description

10.1    Employment Letter Agreement, effective as of July 27, 2017 by and between Applied Genetic Technologies Corporation and William A. Sullivan. Filed herewith.
10.2    Separation Agreement, dated as of July 27, 2017 by and between Applied Genetic Technologies Corporation and Lawrence E. Bullock. Filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

APPLIED GENETIC TECHNOLOGIES

         CORPORATION

By:  

  /s/ Susan B. Washer

  Susan B. Washer
  President and Chief Executive Officer

Date: August 2, 2017

Exhibit 10.1

LOGO

July 26, 2017

William A. Sullivan

Dear Bill,

Applied Genetic Technologies Corporation (the “Company”, “AGTC”) is pleased to offer you a full-time position as Chief Financial Officer beginning at an annual base salary of $340,000 . Your net compensation will be less applicable deductions, taxes, and other amounts required by federal and state laws. This offer is contingent upon satisfactory completion of reference and background checks. Your start date will be August 7 th , 2017 or at a time mutually agreed by you and the company.

You will be eligible to participate in the management performance bonus plan. You will be eligible for a bonus of up to 35% of your then annual base salary based on completion of specific goals defined and agreed to at the beginning of each fiscal year (July 1st). The actual amount of the bonus will be subject to the approval of the Board of Directors.

As a Company employee, you will be eligible to enroll in the employee benefit plans and programs as described and provided by our leasing agent TriNet. AGTC is a drug free workplace and you will therefore be required to submit to a drug screening; authorization for this will be sent separately by TriNet. The Company contribution towards health insurance, and other benefits which you may choose, will be approximately $800 per month. If you need to cover any additional family members the Company will pay an additional amount equal to 50% of the difference between individual coverage and family coverage. The Company also offers its employees participation in a 401(k) plan also administered through TriNet and matches each employee’s contribution up to a maximum of 4% of their annual salary . Each employee has full control over investment vehicle selection and monitoring.

The Company has set up an Employee Incentive Stock Option Plan in which you are eligible to participate. Upon formal approval by the Board of Directors, you will be issued options with an exercise price as determined by the Board to be Fair Market Value at the time of their grant. These options will vest over a period of four years, with 25% vesting initially on the one-year anniversary of the date of your start date and 1/48 each month thereafter until all the shares subject to the option have vested on the fourth anniversary of your start date. If there is a Change of Control and you are not offered the position of CFO at the acquiring company, then immediately upon the Change of Control your options will fully and immediately vest and become exercisable. For purposes of this letter agreement, a “Change of Control” shall mean the occurrence of any of the following events other than in connection with the consummation of an initial public offering of the Company’s securities. In all respects, the definition of Change in Control shall be interpreted to comply with Section 409A, and any successor statute, regulation and guidance thereto: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) who is not a shareholder of the Company as of the date of this letter agreement or an affiliate thereof is or becomes the “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing

 

One Kendall Square, 1400W, Suite B14305, Cambridge, MA 02139  ●  617.843.5728  ●   agtc.com


William A. Sullivan   

July 26, 2017

Page 2 of 5

 

50% or more of the total voting power represented by the Company’s then outstanding voting securities; (ii) the date of the consummation of a merger, scheme of arrangement or consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger, scheme of arrangement or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity} more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation; or (iii) the date of the consummation of the sale or disposition by the Company of alt or substantially all of the Company’s assets.

Initially, you will be entitled to 20 days of Paid Time Off, based on your employment anniversary date in addition to the standard company holidays as described in our Employee Manual. The time will be accrued on a bi-weekly basis and may be used as soon as it is earned. You will receive one additional day per year for each full year of employment based on your anniversary date, up to a maximum of 30 days. This time is for you to use as needed for vacation, family business, sick days or other necessary time away from work. Such leave may be accumulated over three years but in no event shall your leave be accrued in excess of 45 days per year. If your employment terminates for any reason whatsoever, you shall be entitled to receive, in addition to any unpaid salary, any unused PTO accrued to the date of your termination of employment but not to exceed 45 days.

The Company has the right to modify, amend or terminate any such plans and programs described in this letter, as well as its Employee Manual, at any time at its sole discretion.

The Company will reimburse you for all reasonable and necessary traveling expenses and other disbursements actually incurred by you for or on behalf of the Company in the performance of your duties during your employment. This includes qualified transportation reimbursement for a transit pass and/or qualified parking up to the allowable IRS monthly limit. As with other employees, you shall be required to submit to the Company every two weeks reports of claims of such expenses and disbursements for approval and reimbursement by the Company.

Additionally, on a case by case basis we will review Company reimbursement for educational expenses . In cases where your educational courses are mutually beneficial to the Company, the Company will reimburse you for up to one class that you successfully complete per semester.

The Company conducts performance reviews on all personnel in July of each year. Consideration is given for salary increases annually during the review period but going through the review process in itself does not mandate that an employee will receive a raise. The employee’s performance and progression will dictate what ongoing salary levels and bonus opportunities will be.

As you are aware, your employment by the Company is intended to be full-time employment and you will be required to devote all your working time to the business of the Company and not to engage in any other business or private services to any other business either as an employee, officer, director, agent, contractor or consultant, except with the express written consent of the Company. You will hold in a fiduciary capacity for the benefit of the Company, all information with respect to the Company’s finances, sales, profits, and other proprietary and confidential information acquired by you during your employment. In furtherance of this condition of your employment, the Company requires that you sign the Nondisclosure, Inventions and Non-Competition Agreement enclosed with this letter.

 

One Kendall Square, 1400W, Suite B14305, Cambridge, MA 02139  ●  617.843.5728  ●   agtc.com


William A. Sullivan   

July 26, 2017

Page 3 of 5

 

This letter agreement is not intended to and it does not create any employment contract for any specified term or duration between you and the Company. Your employment with the Company is terminable at any time, by yourself upon two weeks written notice, or by the Company upon two weeks written notice or payment of salary in lieu thereof. Your employment may also be terminated for cause by the Company at any time without advance written notice. “Cause” is defined for purposes of your employment as including (but it is not limited to) any of the following:

 

    Your failure to effectively carry out your duties and responsibilities, as evaluated and determined by the Company in its absolute discretion;

 

    Violation of requirements of this letter, the Employee Manual, or any provision of an applicable code of conduct or ethics;

 

    Conduct which, in the Company’s determination, causes embarrassment or loss of credibility to the Company, its employees, products or services, or the position that you hold, or which causes the Board to lose confidence in you.

 

    Conduct which, in the Company’s determination, violates the Nondisclosure, Inventions and Non-Competition Agreement, or which involves dishonesty, moral turpitude, or misrepresentation.

For purposes of this letter agreement, “Good Reason” shall mean:

 

    Either before or after a Change in Control, a requirement that you either (i) perform the majority of your services to the Company in any location beyond a fifty (50) mile radius of Cambridge, Massachusetts; and/or (ii) relocate your residence beyond a fifty (50) mile radius of North Andover, Massachusetts;

 

    Upon the sale of all or substantially all of the stock or assets of the Company, whether by merger, acquisition or otherwise~ the successor company does not offer you a position with substantially equivalent responsibilities; and/or

 

    Upon the sale of all or substantially all of the stock or assets of the Company, whether by merger, acquisition or otherwise, the successor company does not offer you a position with total compensation and benefits at least equivalent to those you received from the Company immediately prior to such sale.

Assuming that you have effectively worked in your new position for a period of at least six months, then if your employment is terminated because either (A) the Company terminates your employment without Cause or (B) you terminate your employment for Good Reason (and provided that you execute and do not revoke a Release and Settlement Agreement in the form reasonably acceptable to the Company and you), you will be entitled to receive an amount equal to nine (9) months’ of your then-base salary for the first year of your employment, or twelve {12) months’ of your then-base salary after the first year; to

 

One Kendall Square, 1400W, Suite B14305, Cambridge, MA 02139  ●  617.843.5728  ●   agtc.com


William A. Sullivan   

July 26, 2017

Page 4 of 5

 

include base salary and bonus earned (less all applicable deductions), plus the Company’s payment of the Company portion of the premium for benefits that you continue pursuant to the Consolidated Omnibus Benefits Reconciliation Act of 1984, as amended, payable in a lump sum or as otherwise agreed to by you and the Company.

Upon termination of your employment with the Company and prior to your departure from the Company, you agree to submit to an exit interview for the purposes of reviewing this letter agreement, the Nondisclosure, Inventions and Non-Competition Agreement and the trade secrets of the Company, and surrendering to the Company all proprietary or confidential information and articles belonging to the Company.

By your signature below, you represent and warrant to the Company that you are not subject to any employment, non-competition or other similar agreement that would prevent or interfere with the Company’s employment of you on the terms set forth herein.    

This letter agreement, the Nondisclosure, Inventions and Non-Competition Agreement and all ancillary agreements (collectively, the “Agreements”) shall be governed by the laws of the State of Delaware. The Agreements constitute the entire agreement between the Company and you, and supersede any and all previous oral or written representation, communication, understanding or agreement between us. Any and all changes or amendments to the Agreements shall be made in writing and signed by the parties.

If the foregoing accurately reflects your expectations for employment at the Company, we would appreciate your returning to us a copy of this letter duly signed and dated in the space provided, whereupon this letter agreement shall become binding upon you and the Company. This offer is valid through July  28, 2017 .

 

One Kendall Square, 1400W, Suite B14305, Cambridge, MA 02139  ●  617.843.5728  ●   agtc.com


William A. Sullivan   

July 26, 2017

Page 5 of 5

 

Finally, it is with great pleasure that I offer you this position at AGTC. The Company is delighted with the prospect of your joining our team. We have exciting and challenging work ahead of us!

Sincerely,

/s/ Susan Washer

Susan Washer

President and CEO

Consented to and Agreed:

 

  /s/ William A. Sullivan

   

  7/27/17                                                     

 
William A. Sullivan     Date  

 

One Kendall Square, 1400W, Suite B14305, Cambridge, MA 02139  ●  617.843.5728  ●   agtc.com

Exhibit 10.2

LOGO

July 27, 2017

Larry Bullock

Dear Larry:

This letter agreement (“Agreement”) will confirm the terms of your employment transition and separation from Applied Genetic Technologies Corporation (“AGTC” or the “Company”), a Florida company. This Agreement will become effective on the eighth day following your execution of it, as described in Section 9 below (the “Effective Date”).

1. Transition and Resignation of Employment. Your voluntary resignation of your employment with AGTC will take effect on September 14, 2017, or a date mutually agreed to by the parties. For the purposes of this Agreement, your last date of employment is the “Separation Date.” During the period between the date of this Agreement and the Separation Date (the “Transition Period”), you will focus your efforts on assisting in the transitioning of your current duties and responsibilities, in consultation with and at the direction of the Company’s CEO. During the Transition Period, you will continue to receive your current salary and benefits. You understand and acknowledge that, from and after the Separation Date, you shall have no authority and shall not represent yourself as an employee or agent of the Company or any of its affiliates. Notwithstanding the foregoing, you agree that you will cooperate with the Company’s reasonable requests for information and assistance in connection with the transitioning of your duties.

2. Bonus. Contingent on your execution of this Agreement and it becoming effective as described in Section 8, you will be eligible to receive a bonus in an amount up to $119,350 to be determined in the Company’s sole discretion based on your achievement of the following goals: (i) successful year-end audit with removal of material weakness, (ii) a Sarbanes-Oxley compliant accounting manual is completed, and (iii) successful implementation of a process for monthly financial reporting by department. The bonus, if any, will be determined and paid out by the Board and/or applicable Board committee promptly after its determination.

3. COBRA. Your participation in all Company benefit plans and programs will end on the last day of the month in which the Separation Date occurs. You understand your legal right, pursuant to the Consolidated Omnibus Budget Reconciliation Act (COBRA), after the Separation Date and upon timely completion of the appropriate forms, to continue at your own expense, your medical and dental insurance coverage. Provided that you execute and do not revoke this Agreement, should you elect COBRA

 

14193 NW 119 th Terrace, Suite #10, Alachua, FL 32615  ●  386.462.2204  ●   agtc.com


continuation coverage, for the one-year period following the Separation Date, the Company will contribute to the cost of such coverage at the same level it contributed to your coverage immediately prior to the Separation Date, so long as the Company sponsors a group health plan and you remain eligible for COBRA coverage. The COBRA payments described herein will be made by the Company directly to the Company’s third-party COBRA administrator. You will be responsible for paying the portion of the COBRA premium not paid by the Company.

4. Pay and Benefits Acknowledgement. You acknowledge and understand that, except for the specific financial consideration and other benefits contained in this Agreement, you are not entitled to and shall not receive any additional compensation, consideration or benefits from the Company.

5. Options. Pursuant to the Company’s 2013 Equity and Incentive Plan, the Company has issued you options (“Existing Options”) to purchase shares of the Company’s common stock (the “Existing Option Shares”). In addition, the Company shall grant you an option (the “New Option” and together with the Existing Options, the “Options”) to purchase 4,168 shares of the Company’s common stock (the “New Option Shares” and together with the Existing Option Shares, the “Option Shares”) on or prior the Separation Date, with an exercise price equal to the closing price of the Company’s common stock on the date of grant. The New Option shall vest in equal monthly installments over four months, with the first installment vesting on July 31, 2017 and each successive installment vesting on the last day of each month thereafter, subject to your continued employment with the Company. After the Separation Date, no further vesting will occur, and you will not be able to exercise the Options to purchase any Option Shares that are not vested Option Shares. After the Separation Date, you may exercise the Options in accordance with their terms to purchase some or all of the Vested Shares until the date (the “Option Termination Date”) that is twenty-four (24) months after the Separation Date. On or after the Option Termination Date, the Options will have terminated in accordance with its terms, and you will no longer be able to exercise the Options to purchase any Option Shares. By signing this Agreement, you are agreeing that the Options will be amended to provide for this twenty-four month period for exercise. You acknowledge and understand that amending your Options to provide for an additional period of time to exercise following the Separation Date will cause the Options to no longer qualify as Incentive Stock Options, that they will automatically become Non-statutory Stock Options, and that upon exercise, any spread between the exercise price and the fair market value of the Company’s common stock at that time will become taxable at ordinary income rates, and you agree to satisfy any withholding obligation of the Company with respect to this income.

6. Covenants by You. You acknowledge and agree to the following:

(a) Upon the Separation Date, you will return all property of the Company, including, without limitation, company credit cards, calling cards and any contracts or proposals, Company, documentation, files and other materials relating to the Company, whether in hard copy or electronic (or other) form.

 

14193 NW 119 th Terrace, Suite #10, Alachua, FL 32615  ●  386.462.2204  ●   agtc.com


(b) You continue to be bound by the terms of the Nondisclosure, Inventions and Non-Competition Agreement between you and the Company, which terms are in full force and effect and will survive the termination of your employment with the Company.

(c) You will not make any statements, whether orally or in writing (including in electronic communications) that are professionally or personally disparaging about the Company or its officers, directors, managers, employees or consultants.

(d) You agree that upon request to cooperate with and provide reasonable assistance to the Company and its legal counsel in connection with any litigation (including without limitation arbitration or administrative hearings), administrative or regulatory review or investigations affecting the Company, in which your assistance or cooperation is needed as determined by the Company or its legal counsel. You agree that you will provide reasonable assistance to the Company in connection with any audit or review of any accounting periods, or portions of any accounting periods, ending on or before the Separation Date. The Company will compensate you at the rate of $300.00 per hour for such cooperation and will reimburse you for your reasonable expenses incurred in providing such cooperation. You further agree that, in the event you are subpoenaed by any person or entity (including without limitation any government agency) to give testimony which in any way relates to your employment by the Company or with respect to any relationship with the Company, you will give prompt notice of such request to the Company and will not make any disclosure until the Company has had a reasonable opportunity to contest the right of the requesting person or entity to such disclosure. If you are made a party or threatened to be made a party to any investigation, lawsuit or proceeding (other than an action by or in the right of the Company) by reason of anything done or not done by you pursuant to this Section 6(d), the Company will indemnify you against any and all expenses and liabilities of any type whatsoever (including, but not limited to, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by you in connection with the investigation, defense, settlement or appeal of such proceeding, so long as you, as determined by the board of directors of the Company acting in good faith, acted in good faith and in a manner you reasonably believed to be in, or not opposed to, the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe your conduct was unlawful. The indemnification provided pursuant to the foregoing sentence shall not be an exclusive remedy, but shall be in addition to any rights you may have under the Company’s amended and restated certificate of incorporation or amended and restated bylaws.

(e) You understand that if you breach any of these covenants, such breach shall constitute a material breach of this Agreement, and shall relieve the Company of any further obligations to you under this Agreement.

 

14193 NW 119 th Terrace, Suite #10, Alachua, FL 32615  ●  386.462.2204  ●   agtc.com


7. Release of Claims .

(i) You hereby agree and acknowledge that by signing this Agreement and accepting the pay, benefits and other consideration discussed above, you are waiving your right to assert any and all forms of legal Claims against the Company 1 of any kind whatsoever, arising from the beginning of time through the date you execute this Agreement. With the sole and limited exceptions set forth in paragraph (ii) below, for purposes of this Section 7 the words “Claim” and “Claims” are intended to be as broad as the law allows and to mean: any and all charges, complaints and other form of action against the Company, seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages, or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, equity (including stock or stock options), emotional distress damages, punitive damages, attorneys’ fees and any other costs) against the Company, including, without limitation:

(a) Claims under any Florida, Massachusetts (or any other state) or federal discrimination, fair employment practices or other employment related statute, regulation or executive order (as they may have been amended through the date you sign this Agreement), including but not limited to Chapter 760 of the Florida Statutes, Mass. Gen. L. c. 151B, and the federal Age Discrimination Employment Act;

(b) Claims under any other Florida, Massachusetts (or any other state) or federal employment related statute, regulation or executive order (as they may have been amended through the date you sign this Agreement), including Chapters 447 and 448 and section 440.205 of the Florida Statutes and Mass. Gen. L. c. 149, section 148;

(c) Claims under any Florida, Massachusetts (or any other state) or federal common law theory; and

(d) Any other Claims arising under other state or federal law.

(ii) Notwithstanding the foregoing, this Section 8 shall not release the Company from any obligation expressly set forth in this Agreement, and does not preclude you from filing a charge of discrimination with the United States Equal Employment Opportunity Commission (“EEOC”), but you will not be entitled to any monetary or other relief from the EEOC or from any Court as a result of litigation brought on the basis of or in connection with such charge.

(iii) You expressly acknowledge and agree that, but for providing the foregoing release of Claims, you would not be receiving the pay and benefits being provided to you under the terms of this Agreement.

 

1   For purposes of this Section, the term “Company” includes Applied Genetic Technologies Corporation and any of its divisions, affiliates (which means all persons and entities directly or indirectly controlling, controlled by or under common control with AGTC), parents, subsidiaries and all other related entities, and its and their directors, officers, employees, trustees, agents, successors and assigns.

 

14193 NW 119 th Terrace, Suite #10, Alachua, FL 32615  ●  386.462.2204  ●   agtc.com


8. Understanding this Agreement. Before signing this Agreement, you should take whatever steps you believe are necessary to ensure that you understand what you are signing, what benefits you are receiving and what rights you are giving up.

(a) By signing this Agreement, you are acknowledging that you have read it carefully and understand all of its terms.

(b) You understand and acknowledge that, if you do not sign this Agreement, including the Release of Claims, you would not be receiving the consideration described in Sections 2, 3 and 5.

(c) You understand that, among other claims you are releasing in the Release of Claims are any claims against the Company alleging discrimination on the basis of age and claims for wages and/or overtime pay under Florida and Massachusetts law .

(d) You are hereby advised and encouraged to consult with legal counsel for the purpose of reviewing the terms of this Agreement.

(e) You are being given twenty-one (21) days in which to consider this Agreement and whether to accept this Agreement. If you choose to accept this Agreement within that time, you are to sign and date below and return it to the Company, care of Sue Washer, 14193 NW 119 th Terrace, Suite 10, Alachua, FL 32615.

(f) Even after executing this Agreement, you have seven (7) days after signing to revoke this Agreement. The Agreement will not be effective or enforceable until this seven (7) day period has expired. In order to revoke your assent to this Agreement, you must, within seven (7) days after you sign this Agreement, deliver a written notice of rescission to Sue Washer at the address noted above. To be effective, the notice of rescission must be hand delivered, or postmarked within the seven (7) day period and sent by certified mail, return receipt requested, to the referenced address.

9. Entire Agreement. You understand and agree that this Agreement constitutes the full extent of the Company’s commitment to you. You further understand and agree that this Agreement supersedes any prior agreements between you and the Company, except to the extent other agreements are specifically referenced herein and incorporated into this Agreement. No changes to this Agreement will be valid unless reduced to writing and signed by you and the Company.

10. Choice of Law/Enforceability. Agreement is made and entered into in the State of Florida and shall be governed by and construed in accordance with the laws of the State of Florida, except with regard to the conflict of laws rules of such State.

 

14193 NW 119 th Terrace, Suite #10, Alachua, FL 32615  ●  386.462.2204  ●   agtc.com


11. General. By executing this Agreement, you are acknowledging that you have been afforded sufficient time to understand its terms and effects, that your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress, and that neither the Company nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.

Your signature below reflects your understanding of, and agreement to, the terms and conditions set forth above.

 

Very truly yours,
APPLIED GENETIC TECHNOLOGIES CORPORATION
By:  

 /s/ Susan B. Washer

    Susan B. Washer
    President and Chief Executive Officer

 

CONFIRMED AND AGREED:  

 /s/ Larry Bullock

 

 

Larry Bullock  
Dated:   7/27/17                                               

 

14193 NW 119 th Terrace, Suite #10, Alachua, FL 32615  ●  386.462.2204  ●   agtc.com